Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Daniel A. Pollyea, Richard M. Stone, Jessica K. Altman, Gail J. Roboz, Manish R. Patel, Robert H Collins, Ian W. Flinn, Mikkael A. Sekeres, Anthony S. Stein, Hagop M. Kantarjian, Ross L. Levine, Paresh Vyas, Kyle J. MacBeth, Alessandra Tosolini, Jason VanOostendorp, Qiang Xu, Ira Gupta & 7 others Thomas Lila, Alberto Risueno, Katharine E. Yen, Bin Wu, Eyal C. Attar, Martin S. Tallman, Stéphane de Botton

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62%) with relapsed or refractory (R/R) AML received enasidenib, 100 mg/d. Median age was 68 years. Forty-two patients (19.6%) attained complete remission (CR), 19 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall response rate was 38.8% (95% confidence interval [CI], 32.2-45.7). Median overall survival was 8.8 months (95% CI, 7.7-9.6). Response and survival were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Response rates were similar among patients who, at study entry, were in relapse (37.7%) or were refractory to intensive (37.5%) or nonintensive (43.2%) therapies. Sixty-six (43.1%) red blood cell transfusion–dependent and 53 (40.2%) platelet transfusion–dependent patients achieved transfusion independence. The magnitude of 2-HG reduction on study was associated with CR in IDH2-R172 patients. Clearance of mutant-IDH2 clones was also associated with achievement of CR. Among all 345 patients, the most common grade 3 or 4 treatment-related adverse events were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation syndrome (6%). Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered at www.clinicaltrials.gov as #NCT01915498.

Original languageEnglish (US)
Pages (from-to)676-687
Number of pages12
JournalBlood
Volume133
Issue number7
DOIs
StatePublished - Feb 14 2019

Fingerprint

Isocitrate Dehydrogenase
Acute Myeloid Leukemia
Refractory materials
Mutation
Transplants
Platelets
Confidence Intervals
Histones
Arginine
Hyperbilirubinemia
Survival
Bone
Blood
Hematologic Neoplasms
Cells
Thrombocytopenia
Catalytic Domain
Therapeutics
Blood Platelets
Clone Cells

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., ... de Botton, S. (2019). Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood, 133(7), 676-687. https://doi.org/10.1182/blood-2018-08-869008

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. / Stein, Eytan M.; DiNardo, Courtney D.; Fathi, Amir T.; Pollyea, Daniel A.; Stone, Richard M.; Altman, Jessica K.; Roboz, Gail J.; Patel, Manish R.; Collins, Robert H; Flinn, Ian W.; Sekeres, Mikkael A.; Stein, Anthony S.; Kantarjian, Hagop M.; Levine, Ross L.; Vyas, Paresh; MacBeth, Kyle J.; Tosolini, Alessandra; VanOostendorp, Jason; Xu, Qiang; Gupta, Ira; Lila, Thomas; Risueno, Alberto; Yen, Katharine E.; Wu, Bin; Attar, Eyal C.; Tallman, Martin S.; de Botton, Stéphane.

In: Blood, Vol. 133, No. 7, 14.02.2019, p. 676-687.

Research output: Contribution to journalArticle

Stein, EM, DiNardo, CD, Fathi, AT, Pollyea, DA, Stone, RM, Altman, JK, Roboz, GJ, Patel, MR, Collins, RH, Flinn, IW, Sekeres, MA, Stein, AS, Kantarjian, HM, Levine, RL, Vyas, P, MacBeth, KJ, Tosolini, A, VanOostendorp, J, Xu, Q, Gupta, I, Lila, T, Risueno, A, Yen, KE, Wu, B, Attar, EC, Tallman, MS & de Botton, S 2019, 'Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib', Blood, vol. 133, no. 7, pp. 676-687. https://doi.org/10.1182/blood-2018-08-869008
Stein, Eytan M. ; DiNardo, Courtney D. ; Fathi, Amir T. ; Pollyea, Daniel A. ; Stone, Richard M. ; Altman, Jessica K. ; Roboz, Gail J. ; Patel, Manish R. ; Collins, Robert H ; Flinn, Ian W. ; Sekeres, Mikkael A. ; Stein, Anthony S. ; Kantarjian, Hagop M. ; Levine, Ross L. ; Vyas, Paresh ; MacBeth, Kyle J. ; Tosolini, Alessandra ; VanOostendorp, Jason ; Xu, Qiang ; Gupta, Ira ; Lila, Thomas ; Risueno, Alberto ; Yen, Katharine E. ; Wu, Bin ; Attar, Eyal C. ; Tallman, Martin S. ; de Botton, Stéphane. / Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. In: Blood. 2019 ; Vol. 133, No. 7. pp. 676-687.
@article{9a988c0d97694f049eb4dfcad58637e4,
title = "Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib",
abstract = "Approximately 8{\%} to 19{\%} of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62{\%}) with relapsed or refractory (R/R) AML received enasidenib, 100 mg/d. Median age was 68 years. Forty-two patients (19.6{\%}) attained complete remission (CR), 19 patients (10.3{\%}) proceeded to an allogeneic bone marrow transplant, and the overall response rate was 38.8{\%} (95{\%} confidence interval [CI], 32.2-45.7). Median overall survival was 8.8 months (95{\%} CI, 7.7-9.6). Response and survival were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Response rates were similar among patients who, at study entry, were in relapse (37.7{\%}) or were refractory to intensive (37.5{\%}) or nonintensive (43.2{\%}) therapies. Sixty-six (43.1{\%}) red blood cell transfusion–dependent and 53 (40.2{\%}) platelet transfusion–dependent patients achieved transfusion independence. The magnitude of 2-HG reduction on study was associated with CR in IDH2-R172 patients. Clearance of mutant-IDH2 clones was also associated with achievement of CR. Among all 345 patients, the most common grade 3 or 4 treatment-related adverse events were hyperbilirubinemia (10{\%}), thrombocytopenia (7{\%}), and IDH differentiation syndrome (6{\%}). Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered at www.clinicaltrials.gov as #NCT01915498.",
author = "Stein, {Eytan M.} and DiNardo, {Courtney D.} and Fathi, {Amir T.} and Pollyea, {Daniel A.} and Stone, {Richard M.} and Altman, {Jessica K.} and Roboz, {Gail J.} and Patel, {Manish R.} and Collins, {Robert H} and Flinn, {Ian W.} and Sekeres, {Mikkael A.} and Stein, {Anthony S.} and Kantarjian, {Hagop M.} and Levine, {Ross L.} and Paresh Vyas and MacBeth, {Kyle J.} and Alessandra Tosolini and Jason VanOostendorp and Qiang Xu and Ira Gupta and Thomas Lila and Alberto Risueno and Yen, {Katharine E.} and Bin Wu and Attar, {Eyal C.} and Tallman, {Martin S.} and {de Botton}, St{\'e}phane",
year = "2019",
month = "2",
day = "14",
doi = "10.1182/blood-2018-08-869008",
language = "English (US)",
volume = "133",
pages = "676--687",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

AU - Stein, Eytan M.

AU - DiNardo, Courtney D.

AU - Fathi, Amir T.

AU - Pollyea, Daniel A.

AU - Stone, Richard M.

AU - Altman, Jessica K.

AU - Roboz, Gail J.

AU - Patel, Manish R.

AU - Collins, Robert H

AU - Flinn, Ian W.

AU - Sekeres, Mikkael A.

AU - Stein, Anthony S.

AU - Kantarjian, Hagop M.

AU - Levine, Ross L.

AU - Vyas, Paresh

AU - MacBeth, Kyle J.

AU - Tosolini, Alessandra

AU - VanOostendorp, Jason

AU - Xu, Qiang

AU - Gupta, Ira

AU - Lila, Thomas

AU - Risueno, Alberto

AU - Yen, Katharine E.

AU - Wu, Bin

AU - Attar, Eyal C.

AU - Tallman, Martin S.

AU - de Botton, Stéphane

PY - 2019/2/14

Y1 - 2019/2/14

N2 - Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62%) with relapsed or refractory (R/R) AML received enasidenib, 100 mg/d. Median age was 68 years. Forty-two patients (19.6%) attained complete remission (CR), 19 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall response rate was 38.8% (95% confidence interval [CI], 32.2-45.7). Median overall survival was 8.8 months (95% CI, 7.7-9.6). Response and survival were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Response rates were similar among patients who, at study entry, were in relapse (37.7%) or were refractory to intensive (37.5%) or nonintensive (43.2%) therapies. Sixty-six (43.1%) red blood cell transfusion–dependent and 53 (40.2%) platelet transfusion–dependent patients achieved transfusion independence. The magnitude of 2-HG reduction on study was associated with CR in IDH2-R172 patients. Clearance of mutant-IDH2 clones was also associated with achievement of CR. Among all 345 patients, the most common grade 3 or 4 treatment-related adverse events were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation syndrome (6%). Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered at www.clinicaltrials.gov as #NCT01915498.

AB - Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62%) with relapsed or refractory (R/R) AML received enasidenib, 100 mg/d. Median age was 68 years. Forty-two patients (19.6%) attained complete remission (CR), 19 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall response rate was 38.8% (95% confidence interval [CI], 32.2-45.7). Median overall survival was 8.8 months (95% CI, 7.7-9.6). Response and survival were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Response rates were similar among patients who, at study entry, were in relapse (37.7%) or were refractory to intensive (37.5%) or nonintensive (43.2%) therapies. Sixty-six (43.1%) red blood cell transfusion–dependent and 53 (40.2%) platelet transfusion–dependent patients achieved transfusion independence. The magnitude of 2-HG reduction on study was associated with CR in IDH2-R172 patients. Clearance of mutant-IDH2 clones was also associated with achievement of CR. Among all 345 patients, the most common grade 3 or 4 treatment-related adverse events were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation syndrome (6%). Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered at www.clinicaltrials.gov as #NCT01915498.

UR - http://www.scopus.com/inward/record.url?scp=85061474021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061474021&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-08-869008

DO - 10.1182/blood-2018-08-869008

M3 - Article

VL - 133

SP - 676

EP - 687

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -